IDSA Guideline Recommendations for Antibiotic Management of Staphylococcal Foot Infections

1. Methicillin‑Susceptible Staphylococcus aureus (MSSA)

• Oral dicloxacillin 500 mg four times daily is the preferred agent for mild‑to‑moderate outpatient MSSA foot infections (recommended for patients without penicillin allergy) 1, 2.
• Oral cephalexin 500 mg four times daily can be used in patients with non‑immediate penicillin allergy 1, 2.
• Oral clindamycin 300–450 mg three times daily is an alternative, but clinicians should be aware of possible cross‑resistance in erythromycin‑resistant strains 1, 2.
• IV nafcillin or oxacillin 1–2 g every 4 h is the parenteral drug of choice for severe or hospitalized MSSA foot infections; it has no activity against MRSA 1, 2.
• IV cefazolin 1 g every 8 h is appropriate for severe MSSA infections in patients with non‑immediate penicillin allergy 1, 2.

2. Methicillin‑Resistant Staphylococcus aureus (MRSA)

2.1 Outpatient Purulent Cellulitis or Mild‑to‑Moderate Infections

• Empiric coverage for community‑associated MRSA (CA‑MRSA) is recommended for purulent cellulitis while awaiting culture results 3, 4, 5.
• Oral clindamycin 300–450 mg three times daily (A‑I strength) is a first‑line option 3, 4, 5.
• Oral trimethoprim‑sulfamethoxazole (TMP‑SMX) 1–2 double‑strength tablets twice daily (A‑II) is an alternative 3, 4, 5.
• Oral doxycycline or minocycline 100 mg twice daily (A‑II) is another alternative 3, 4, 5.

• Oral linezolid 600 mg twice daily (A‑II) can be used when other agents are unsuitable 3, 4, 5.

• If dual coverage for β‑hemolytic streptococci and CA‑MRSA is desired, options include:

  • Clindamycin alone,
  • TMP‑SMX or a tetracycline combined with a β‑lactam such as amoxicillin,
  • Linezolid alone 3, 4, 5.

2.2 Outpatient Non‑purulent Cellulitis

• Initial empiric therapy should target β‑hemolytic streptococci; MRSA coverage is added only if there is treatment failure or systemic toxicity 3, 4, 5.

2.3 Hospitalized Patients with Complicated SSTI

• Empiric MRSA therapy should be considered pending culture data for deep infections, major abscesses, or infected ulcers 3, 4, 5.
• IV vancomycin (A‑I) dosed to achieve therapeutic trough levels is a primary option 3, 4, 5.
• IV or PO linezolid 600 mg twice daily (A‑I) is an alternative 3, 4, 5.
• IV daptomycin 4 mg/kg once daily (A‑I) is appropriate for MRSA coverage 3, 4, 5.
• IV telavancin 10 mg/kg once daily (A‑I) may be used when vancomycin is unsuitable 3, 4, 5.
• IV/PO clindamycin 600 mg three times daily (A‑III) is a lower‑strength alternative 3, 4, 5.

3. Diabetic Foot Infections

• Mild diabetic foot infections are most often caused by gram‑positive cocci; oral cloxacillin or a first‑generation cephalosporin (e.g., cephalexin) is appropriate for uncomplicated cases 6, 7.
• In patients with β‑lactam allergy, options include clindamycin, a fluoroquinolone (levofloxacin or moxifloxacin), TMP‑SMX, or doxycycline 6.
• Moderate‑to‑severe diabetic foot infections require broader empiric coverage; oral amoxicillin/clavulanate 875/125 mg twice daily is recommended 8, 2.
• Levofloxacin can be used when broader gram‑positive and gram‑negative activity is needed 8.

4. Duration of Therapy

• For uncomplicated skin and soft‑tissue infections, a total of 5–10 days of therapy is advised; a 5‑day course is as effective as 10 days if clinical improvement is evident by day 5 3, 4, 5, 7.
• For complicated infections requiring hospitalization, 7–14 days of therapy is recommended 3, 4, 5.

5. Procedural Management

• Incision and drainage (I&D) is the primary treatment for cutaneous abscesses (A‑II) 3, 4, 5.
• Adjunctive antibiotics are indicated for:
  
  • Severe or extensive disease involving multiple sites,
  • Rapid progression with surrounding cellulitis,
  • Systemic signs of illness,
  • Significant comorbidities or immunosuppression,
  • Extremes of age,
  • Abscesses in difficult‑to‑drain locations (e.g., face, hand, genitalia),
  • Lack of response to I&D alone 3, 4, 5.

6. Safety and Contraindications

• Rifampin should not be used as a single agent or as adjunctive therapy for SSTI (A‑III) 3, 4, 5.
• MRSA is an uncommon cause of typical non‑purulent cellulitis; β‑lactam therapy (e.g., cefazolin or oxacillin) achieved clinical success in ~96 % of cases, so routine MRSA coverage is unnecessary for classic cellulitis 7.
• MRSA coverage is warranted when cellulitis is associated with penetrating trauma (especially injection drug use), purulent drainage, or a concurrent MRSA infection elsewhere 7.
• TMP‑SMX demonstrates 95–100 % in‑vitro susceptibility against CA‑MRSA strains 3; however, caution is advised in elderly patients on renin‑angiotensin system inhibitors or with chronic renal insufficiency due to the risk of hyperkalemia 3.
• Tetracyclines (including doxycycline and minocycline) should not be prescribed to children younger than 8 years 4, 5, 9.